|Day's Range||2,525,000.00 - 2,538,000.00|
|52 Week Range||1,456,000.00 - 2,566,000.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 27, 2017|
|Dividend & Yield||25.45 (1.22%)|
|1y Target Est||N/A|
South Korea’s Samsung conglomerate, best known for its smartphones and televisions, will make available in the U.S. its lower-price copy of Johnson & Johnson’s blockbuster arthritis drug Remicade.
Samsung's Active version of the Galaxy S8 is said to feature a flat 5.8-inch display, Bixby button, and Android O.
Chipmaker AMS, which supplies components to Apple and Samsung Electronics among others, on Monday raised its mid-term revenue growth target, thanks to increased customer forecasts and a higher revenue pipeline. The company said in April it might raise mid-term revenue growth target as it expected significant ramp-ups in its consumer business in the second half of the year. AMS said its revenue growth target for 2016-2019 would rise to a more than 40 percent compound annual growth rate and it confirmed an adjusted core profit margin target of 30 percent from 2019 onwards.